Inventor
FRANK-KAMENETSKY MARIA
US36 patents
⚠️ This page may combine multiple inventors who share the name “FRANK-KAMENETSKY MARIA”. Patents are grouped by organization below to help distinguish them — per-person disambiguation is on the roadmap.
ALNYLAM PHARMACEUTICALS INC
26 patentsUS7605251B2Oct 20, 2009
Compositions and methods for inhibiting expression of the PCSK9 gene
ALNYLAM PHARMACEUTICALS INC160 citations99
US10337010B2Jul 2, 2019
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC17 citations98
US9771591B2Sep 26, 2017
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC22 citations98
US9322018B2Apr 26, 2016
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC36 citations98
US7582745B2Sep 1, 2009
Compositions and methods for inhibiting expression of Nav1.8 gene
ALNYLAM PHARMACEUTICALS INC152 citations98
US11525138B2Dec 13, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC7 citations94
US11332743B2May 17, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations94
US11306314B2Apr 19, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations94
US11306315B2Apr 19, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations94
US11306316B2Apr 19, 2022
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations94
US10557139B2Feb 11, 2020
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC15 citations94
US10550390B2Feb 4, 2020
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC15 citations94
US7947659B2May 24, 2011
iRNA agents targeting VEGF
ALNYLAM PHARMACEUTICALS INC26 citations93
US7919473B2Apr 5, 2011
IRNA agents targeting VEGF
ALNYLAM PHARMACEUTICALS INC29 citations93
US11130953B2Sep 28, 2021
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC8 citations92
US11866709B2Jan 9, 2024
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations86
US11840692B2Dec 12, 2023
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations84
US11834662B2Dec 5, 2023
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC3 citations84
US10934545B2Mar 2, 2021
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC6 citations84
US10125369B2Nov 13, 2018
PCSK9 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC9 citations84
US9822365B2Nov 21, 2017
Compositions and methods for inhibiting expression of the PCSK9 gene
ALNYLAM PHARMACEUTICALS INC3 citations84
US9260718B2Feb 16, 2016
Compositions and methods for inhibiting expression of the PCSK9 gene
ALNYLAM PHARMACEUTICALS INC6 citations84
US12467051B2Nov 11, 2025
Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations73
US10501742B2Dec 10, 2019
Compositions and methods for inhibiting expression of the PCSK9 gene
ALNYLAM PHARMACEUTICALS INC1 citations73
US12460206B2Nov 4, 2025
PCSK9 iRNA compositions and methods of use thereof
ALNYLAM PHARMACEUTICALS INC0 citations62
US7902168B2Mar 8, 2011
Compositions and methods for inhibiting expression of Nav1.8 gene
ALNYLAM PHARMACEUTICALS INC1 citations52